Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
In mammalians, toll-like receptors (TLR) signal-transduction pathways induce the expression of a variety of immune-response genes, including inflammatory cytokines. It is therefore plausible to assume that TLRs are mediators in glial cells triggering the release of cytokines that ultimately kill DA neurons in the substantia nigra in Parkinson disease (PD). Accordingly, recent data indicate that TLR4 is up-regulated by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment in a mouse model of PD. Here, we wished to evaluate the role of TLR4 in the acute mouse MPTP model of PD: TLR4-deficient mice and wild-type littermates control mice were used for the acute administration way of MPTP or a corresponding volume of saline. We demonstrate that TLR4-deficient mice are less vulnerable to MPTP intoxication than wild-type mice and display a decreased number of Iba1+ and MHC II+ activated microglial cells after MPTP application, suggesting that the TLR4 pathway is involved in experimental PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“TLR4 gene-deficient mice partially resist MPTP toxicity by suppressing the activation of microglia in the substantia nigra.156”
From The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options (2021) · cites this paper as [156]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Defective LPS Signaling in C3H/HeJ and C57BL/10ScCr Mice: Mutations in Tlr4 Gene
Poltorak, A., He, X., Smirnova, I., Liu, M.-Y., Huffel, C. V., Du, X., Birdwell, D., Alejos, E., Silva, M., Galanos, C., et al. (1998) · Science · doi:10.1126/science.282.5396.2085 · Cited by 7,631
mouse brain in stereotaxic coordinates
Franklin, K. B. J., & Paxinos, G. (1997) · Cited by 3,258
McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990
Neuroinflammation in Parkinson’s disease: A target for neuroprotection?
Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984
Self-citationMelanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease
Hirsch, E., Graybiel, A. M., & Agid, Y. A. (1988) · Nature · doi:10.1038/334345a0 · Cited by 1,301
Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthat, V., Bonduelle, O., Alvarez-Fischer, D., Callebert, J., Launay, J.-M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36470 · Cited by 1,172
Self-citationTargeting Toll-like receptors: emerging therapeutics?
Hennessy, E. J., Parker, A. E., & O'Neill, L. A. J. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3203 · Cited by 886
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists
Kanzler, H., Barrat, F. J., Hessel, E. M., & Coffman, R. L. (2007) · Nature Medicine · doi:10.1038/nm1589 · Cited by 869
LAFLAMME, N., & RIVEST, S. (2001) · The FASEB Journal · doi:10.1096/fj.00-0339com · Cited by 501
Moresco, E. M. Y., LaVine, D., & Beutler, B. (2011) · Current Biology · doi:10.1016/j.cub.2011.05.039 · Cited by 500
Research works printed but not linked: 1
- Fahn S., Parkinsonism P. S., & Rowland L. P. ed. Meritt's neurology 10th ed. New York: Lippincott, 2000, 679–693 (2000).
Cited by
Innate immune activation in neurodegenerative disease
Heneka, M. T., Kummer, M. P., & Latz, E. (2014) · Nature Reviews Immunology · doi:10.1038/nri3705 · Cited by 1,437
Microglia-mediated neuroinflammation in neurodegenerative diseases
Subhramanyam, C. S., Wang, C., Hu, Q., & Dheen, S. T. (2019) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2019.05.004 · Cited by 870
Microglia in Neurological Diseases: A Road Map to Brain-Disease Dependent-Inflammatory Response
Bachiller, S., Jiménez-Ferrer, I., Paulus, A., Yang, Y., Swanberg, M., Deierborg, T., & Boza-Serrano, A. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00488 · Cited by 707
“These neurons project their axons from the SNpc to the striatum.”
BackgroundInfluentialLiu, W., Rong, Y., Wang, J., Zhou, Z., Ge, X., Ji, C., Jiang, D., Gong, F., Li, L., Chen, J., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-020-1726-7 · Cited by 573
Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
Dong-Chen, X., Yong, C., Yang, X., Chen-Yu, S., & Li-Hua, P. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01353-3 · Cited by 469
“observed that TLR-4 knockout lowered the number of activated microglial cells and protected against SN dopaminergic degeneration, demonstrating that TLR-4 contributes to neuroinflammation.(174) Adaptive immune responses also factor into neuroinflammation during PD.”
BackgroundThe Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation
Molteni, M., Gemma, S., & Rossetti, C. (2016) · Mediators of Inflammation · doi:10.1155/2016/6978936 · Cited by 446
“In a mouse model of PD induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), TLR4 was shown to mediate cell death of dopaminergic neurons and TLR4-deficient mice were partially protected against MPTP toxicity [98].”
BackgroundExploring Braak’s hypothesis of Parkinson’s disease
Rietdijk, C. D., Perez-Pardo, P., Garssen, J., van Wezel, R. J. A., & Kraneveld, A. D. (2017) · Frontiers in Neurology · doi:10.3389/fneur.2017.00037 · Cited by 395
González, H., Elgueta, D., Montoya, A., & Pacheco, R. (2014) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2014.07.012 · Cited by 352
Microbiome-Gut-Brain Axis and Toll-Like Receptors in Parkinson’s Disease
Caputi, V., & Giron, M. C. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061689 · Cited by 338
Toll-like receptors in the pathogenesis of neuroinflammation
Kumar, V. (2019) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2019.03.012 · Cited by 331
Innate Immunity and Neurodegeneration
Labzin, L. I., Heneka, M. T., & Latz, E. (2018) · Annual Review of Medicine · doi:10.1146/annurev-med-050715-104343 · Cited by 319
Role of Microglia TLRs in Neurodegeneration
Fiebich, B. L., Batista, C. R. A., Saliba, S. W., Yousif, N. M., & de Oliveira, A. C. P. (2018) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2018.00329 · Cited by 291
TLR Agonists as Vaccine Adjuvants Targeting Cancer and Infectious Diseases
Luchner, M., Reinke, S., & Milicic, A. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020142 · Cited by 285
The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options
Wang, Q., Luo, Y., Ray Chaudhuri, K., Reynolds, R., Tan, E.-K., & Pettersson, S. (2021) · Brain · doi:10.1093/brain/awab156 · Cited by 281
Qin, H., Buckley, J. A., Li, X., Liu, Y., Fox, T. H., Meares, G. P., Yu, H., Yan, Z., Harms, A. S., Li, Y., et al. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.4658-15.2016 · Cited by 274
“Ionized calcium binding adaptor molecule 1 (Iba1) was used as marker for activated microglia (Barkholt et al., 2012; Noelker et al., 2013).”
MethodDoorn, K. J., Moors, T., Drukarch, B., van de Berg, W. D., Lucassen, P. J., & van Dam, A.-M. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0090-1 · Cited by 254
“In support of this, TLR-deficient mice are less vulnerable to MPTP toxicity and show decreased microglial activation in the SN after MPTP treatment [45], while (Thy1)[A30P] α-synuclein transgenic mice show a significant upregulation of TLR2 [46].”
BackgroundCheng, J., Liao, Y., Dong, Y., Hu, H., Yang, N., Kong, X., Li, S., Li, X., Guo, J., Qin, L., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1719723 · Cited by 233
Azam, S., Jakaria, M., Kim, I.-S., Kim, J., Haque, M. E., & Choi, D.-K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01000 · Cited by 226
Ten Unsolved Questions About Neuroinflammation in Parkinson's Disease
Hirsch, E. C., & Standaert, D. G. (2021) · Movement Disorders · doi:10.1002/mds.28075 · Cited by 189
“Indeed, in both in vitro and in vivo models of PD, degenerating neurons release heat shock protein, which acts through the TOLL like receptor 4 at the surface of the microglial cells to activate them.(48,49) Several groups of investigators have also shown that α-synuclein activates microglia in experimental models of…”
BackgroundSvensson, M., Lexell, J., & Deierborg, T. (2015) · Neurorehabilitation and Neural Repair · doi:10.1177/1545968314562108 · Cited by 185
“Preconditioning with physical exercise is well known to ameliorate acute ischemic brain damage in rodents involving restraining of immunological processes,(78) such as TLR4 signaling,(79) that are known to have a similar protective role in experimental neurodegenerative diseases.(80,81) It is therefore reasonable to p…”
BackgroundHughes, C. D., Choi, M. L., Ryten, M., Hopkins, L., Drews, A., Botía, J. A., Iljina, M., Rodrigues, M., Gagliano, S. A., Gandhi, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1907-y · Cited by 177
“While there are potential issues extrapolating from these cell experiments to animals, this finding is also supported by the MPTP inflammatory model of PD, where TLR4 knockout mice were protected [37].”
BackgroundResultThe role of inflammation in sporadic and familial Parkinson’s disease
Deleidi, M., & Gasser, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1352-y · Cited by 167
Crowley, T., Cryan, J. F., Downer, E. J., & O’Leary, O. F. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2016.02.001 · Cited by 150
“…much interest as having a potential role in the progression or etiology of neuroinflammatory disorders such as Multiple Sclerosis (MS) (O'Brien et al., 2008), Parkinson’s disease (PD) (Noelker et al., 2013; Stone et al., 2009) and Alzheimer’s disease (AD) (Tahara et al., 2006; Wang et al., 2011).”
BackgroundToll-like receptors and their therapeutic potential in Parkinson’s disease and α-synucleinopathies
Kouli, A., Horne, C. B., & Williams-Gray, C. H. (2019) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2019.06.042 · Cited by 143
Diet in Parkinson’s Disease: Critical Role for the Microbiome
Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01245 · Cited by 145
Campolo, M., Paterniti, I., Siracusa, R., Filippone, A., Esposito, E., & Cuzzocrea, S. (2019) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.12.003 · Cited by 142
Members, E. W. E., Terron, A., Bal-Price, A., Paini, A., Monnet-Tschudi, F., Bennekou, S. H., Leist, M., & Schildknecht, S. (2018) · Archives of Toxicology · doi:10.1007/s00204-017-2133-4 · Cited by 124
“TLR-4-deficient mice are less vulnerable to MPTP/MPP+ intoxication and display a decreased number of reactive activated glial cells compared with MPTP/MPP+treated wild-type animals (Noelker et al. 2013).”
BackgroundNeal, M. L., Fleming, S. M., Budge, K. M., Boyle, A. M., Kim, C., Alam, G., Beier, E. E., Wu, L., & Richardson, J. R. (2020) · The FASEB Journal · doi:10.1096/fj.201900567rr · Cited by 123
Ren, M., Guo, Y., Wei, X., Yan, S., Qin, Y., Zhang, X., Jiang, F., & Lou, H. (2018) · Experimental Neurology · doi:10.1016/j.expneurol.2018.01.016 · Cited by 126
“Recent studies have suggested that activation of the TLR4 pathway in the central nervous system may have a critical contribution to the pathogenesis of PD (Noelker et al., 2013).”
The role of the immune system in neurodegenerative disorders: Adaptive or maladaptive?
Doty, K. R., Guillot-Sestier, M.-V., & Town, T. (2015) · Brain Research · doi:10.1016/j.brainres.2014.09.008 · Cited by 104
“…PARK2 is regulated by TLR4-MyD88-NF-kB and TNF-α–NF-kBdependent pathways in microglia and macrophages (Tran et al., 2011), suggesting that activation of TLR-dependent pathways could play a role in dysregulation of neuroinflammation during PD progression (Noelker et al., 2013; Panaro et al., 2008).”
TLR2 and TLR4 in Parkinson’s disease pathogenesis: The environment takes a toll on the gut
Gorecki, A. M., Anyaegbu, C. C., & Anderton, R. S. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00271-0 · Cited by 103
Inflammatory response in Parkinson’s disease (Review)
YAN, J., FU, Q., CHENG, L., ZHAI, M., WU, W., HUANG, L., & DU, G. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.2563 · Cited by 101
“Noelker et al (93) demonstrated that TLR4‑deficient mice are less vulnerable to MPTP intoxication than wild-type mice, in addition to displaying a reduced number of ionized calcium-binding adaptor molecule 1(+) and major histocompatibility complex II(+) activated microglial cells following MPTP application.”
Hughes, C. D., Choi, M. L., Ryten, M., Hopkins, L., Drews, A., Botía, J. A., Iljina, M., Rodrigues, M., Taliun, S. A. G., Gandhi, S., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1919-7 · Cited by 100
Neuroinflammation - A major cause for striatal dopaminergic degeneration in Parkinson's disease
Kaur, K., Gill, J. S., Bansal, P. K., & Deshmukh, R. R. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2017.08.3251 · Cited by 112
Main, B. S., Zhang, M., Brody, K. M., Ayton, S., Frugier, T., Steer, D., Finkelstein, D., Crack, P. J., & Taylor, J. M. (2016) · Glia · doi:10.1002/glia.23028 · Cited by 92
“knockout mice display an attenuated loss (13% compared to wildtype mice) of DA neurons in the MPTP model (Noelker et al., 2013).”
BackgroundInterplay Between Exosomes, microRNAs and Toll-Like Receptors in Brain Disorders
Paschon, V., Takada, S. H., Ikebara, J. M., de Sousa, É., Raeisossadati, R., Ulrich, H., & Kihara, A. H. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9142-1 · Cited by 99
“tion has been documented in AD [29, 121], PD [121, 122],”
BackgroundGrotemeyer, A., McFleder, R. L., Wu, J., Wischhusen, J., & Ip, C. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.878771 · Cited by 90
Kumaran, R., & Cookson, M. R. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv236 · Cited by 86
“TLR4 has specifically been shown to mediate cell death in a murine MPTP model of PD (70) whilst polymorphisms in the TLR4 gene were recently proposed to alter the risk of developing sporadic PD in Han Chinese population (71), although this result has not been replicated at the time of writing.”
ResultFang, X. (2016) · International Journal of Neuroscience · doi:10.3109/00207454.2015.1096271 · Cited by 86
“One study suggests that the TLR4 pathway contributed to the loss of dopaminergic neurons in a MPTP mouse model of PD [41].”
BackgroundEmerging Role of Sirtuin 2 in Parkinson’s Disease
Liu, Y., Zhang, Y., Zhu, K., Chi, S., Wang, C., & Xie, A. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00372 · Cited by 94
Kim, D., Cho, J., & Kang, H. (2019) · Behavioural Brain Research · doi:10.1016/j.bbr.2019.112105 · Cited by 89
Yu, S., Wang, X., He, X., Wang, Y., Gao, S., Ren, L., & Shi, Y. (2016) · Cell Stress and Chaperones · doi:10.1007/s12192-016-0695-3 · Cited by 89
TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson’s disease
Shao, Q.-H., Chen, Y., Li, F.-F., Wang, S., Zhang, X.-L., Yuan, Y.-H., & Chen, N.-H. (2019) · Acta Pharmacologica Sinica · doi:10.1038/s41401-019-0280-2 · Cited by 81
Autophagy regulates MAVS signaling activation in a phosphorylation-dependent manner in microglia
Cheng, J., Liao, Y., Xiao, L., Wu, R., Zhao, S., Chen, H., Hou, B., Zhang, X., Liang, C., Xu, Y., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.121 · Cited by 82
Roser, A.-E., Tönges, L., & Lingor, P. (2017) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2017.00094 · Cited by 77
Neurotoxin Mechanisms and Processes Relevant to Parkinson’s Disease: An Update
Segura‐Aguilar, J., & Kostrzewa, R. M. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9519-y · Cited by 81
“The guanylhydrazone, p38 MAP kinase inhibitor CNI- 1493, another anti-inflammatory agent that protects C57BL/6 mice from MPTP (Noelker et al. 2013); f.”
BackgroundThe Dual Role of Hepcidin in Brain Iron Load and Inflammation
Vela, D. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00740 · Cited by 73
Shin, W.-H., Jeon, M.-T., Leem, E., Won, S.-Y., Jeong, K. H., Park, S.-J., McLean, C., Lee, S. J., Jin, B. K., Jung, U. J., et al. (2015) · Scientific Reports · doi:10.1038/srep14764 · Cited by 64
Ceramides in Parkinson’s Disease: From Recent Evidence to New Hypotheses
Plotegher, N., Bubacco, L., Greggio, E., & Civiero, L. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00330 · Cited by 68
Role of Innate Immune Receptor TLR4 and its endogenous ligands in epileptogenesis
Paudel, Y. N., Angelopoulou, E., Akyüz, E., Piperi, C., Othman, I., & Shaikh, M. F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.105172 · Cited by 63
Martin, H. L., Santoro, M., Mustafa, S., Riedel, G., Forrester, J. V., & Teismann, P. (2016) · Glia · doi:10.1002/glia.22935 · Cited by 61
“Additionally, ablation of TLR4 provided neuroprotection in the MPTP-model of PD (Noelker et al., 2013).”
BackgroundElgueta, D., Aymerich, M. S., Contreras, F., Montoya, A., Celorrio, M., Rojo-Bustamante, E., Riquelme, E., González, H., Vásquez, M., Franco, R., et al. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.09.028 · Cited by 67
“Since microglial cells may stimulate both innate and adaptive immunity in the central nervous system (CNS), these cells play a central role in neuroinflammation (Gonzalez et al., 2014; Harms et al., 2013; Noelker et al., 2013; Reynolds et al., 2008, 2009; SanchezGuajardo et al., 2015).”
BackgroundRietdijk, C. D., Van Wezel, R. J. A., Garssen, J., & Kraneveld, A. D. (2016) · Neuroimmunology and Neuroinflammation · doi:10.20517/2347-8659.2015.28 · Cited by 59
“1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment.[95,96] Furthermore, TLR4 and α-synuclein”
Kaur, G., Behl, T., BUNGAU, S. G., Kumar, A., Uddin, M. S., Mehta, V., Zengin, G., Mathew, B., Shah, M. A., & Arora, S. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200606233050 · Cited by 63
“These results have been substantiated in a murine model induced by MPTP, wherein the genetic exclusion of TLR-4 transmitting, preserved the mice against deterioration of neurons, demonstrating the chief function of TLR4 in the inflammatory signaling during PD [124].”
ResultToll-like receptor-4 regulates anxiety-like behavior and DARPP-32 phosphorylation
Femenía, T., Qian, Y., Arentsen, T., Forssberg, H., & Heijtz, R. D. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2017.11.022 · Cited by 64
“…the role of TLRs in the brain have shown that TLR type 4 receptors (TLR4) are involved in learning and memory (Okun et al., 2012), aging (Letiembre et al., 2007), and neurodegenerative disorders such as Parkinson’s disease (Noelker et al., 2013) and Alzheimer’s disease (Walter et al., 2007).”
BackgroundCheng, L., Chen, L., Wei, X., Wang, Y., Ren, Z., Zeng, S., Zhang, X., Wen, H., Gao, C., & Liu, H. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1289-z · Cited by 52
Uriarte Huarte, O., Kyriakis, D., Heurtaux, T., Pires-Afonso, Y., Grzyb, K., Halder, R., Buttini, M., Skupin, A., Mittelbronn, M., & Michelucci, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.639613 · Cited by 52
“Specifically, TLR4 is involved in microglia activation linked to PD and the lack of Tlr4 in a PD-likemodel ofMPTP resulted in a reducedmicroglia activation and a decreased neurodegeneration (60).”
BackgroundMcCarty, M. F., & Lerner, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21103624 · Cited by 51
TLR-Mediated Signal Transduction and Neurodegenerative Disorders
Adhikarla, S. V., Jha, N. K., Goswami, V. K., Sharma, A., Bhardwaj, A., Dey, A., Villa, C., Kumar, Y., & Jha, S. K. (2021) · Brain Sciences · doi:10.3390/brainsci11111373 · Cited by 50
“These observations suggest that TLR4 might be neuroprotective in the context of PD, as TLR4 could help in the clearance of toxic aggregates but could cause neurodegeneration in the context of toxin-induced PD, for example in patients who are in contact with agents such as MPTP or rotenone.”
BackgroundMechanistic insights on TLR-4 mediated inflammatory pathway in neurodegenerative diseases
Sharma, V., Sharma, P., & Singh, T. G. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00613-5 · Cited by 51
“Neuroprotection was observed in a mouse model of PD induced by 1-Methyl-4-phenyl-1, 2, 3, 6-tetra-hydropyridine (MPTP), when TLR-4 was deleted genetically, confirming its role in the progression of PD [46].”
García-González, P. A., Cabral‐Miranda, F., Hetz, C. A., & Osorio, F. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.02541 · Cited by 50
Heat shock protein 60: an endogenous inducer of dopaminergic cell death in Parkinson disease
Noelker, C., Morel, L. J., Osterloh, A., Alvarez‐Fischer, D., Lescot, T., Breloer, M., Gold, M., Oertel, W. H., Henze, C., Michel, P. P., et al. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-86 · Cited by 49
“However, the endogenous activator of TLR4 in this scenario could not be identified [49].”
BackgroundSelf-citationSaini, N., Akhtar, A., Chauhan, M., Dhingra, N., & Pilkhwal Sah, S. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.08.001 · Cited by 42
McCarty, M. F., & Assanga, S. B. I. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.06.032 · Cited by 43
The role of innate immunity and inflammation in Parkinson´s disease
Öberg, M., Fabrik, I., Fabriková, D., Zehetner, N., & Härtlová, A. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13022 · Cited by 43
Haddadi, R., Nayebi, A. M., & Brooshghalan, S. E. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.05.020 · Cited by 39
RetractedJoshi, P., Bisht, A., Joshi, S., Semwal, D. K., Nema, N. K., Dwivedi, J., & Sharma, S. K. (2022) · Phytotherapy Research · doi:10.1002/ptr.7522 · Cited by 41
“Its common symptoms include ataxia, dormant tremor, and dopaminergic neurons loss in the black bone striatum (Noelker et al., 2013).”
BackgroundVinpocetine regulates levels of circulating TLRs in Parkinson’s disease patients
Ping, Z., Wu, X., Xufang, X., & Shao, L. (2018) · Neurological Sciences · doi:10.1007/s10072-018-3592-y · Cited by 38
Khan, M. S., Nasiripour, S., & Bopassa, J. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136416 · Cited by 57
“Furthermore, pharmacological inhibition or CD4 T cell deletion reduces the expression of major histocompatibility complex (MHC) II in CNS myeloid cells and guards against the loss of tyrosine hydroxylase (TH) neurons in the ipsilateral SN pars compacta (SNpc) [177–181].”
TLR7/8 in the Pathogenesis of Parkinson’s Disease
Campolo, M., Filippone, A., Biondo, C., Mancuso, G., Casili, G., Lanza, M., Cuzzocrea, S., Esposito, E., & Paterniti, I. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249384 · Cited by 38
“In particular, recent papers have focused the attention only on the roles of extracellular TLR, such as 2 and 4, in the pathogenesis of PD [20,21], never looking to the involvement of the other TLRs, such as the intracellular TLR7, 8, and 9 in PD etiology.”
BackgroundThe Role of Bilirubin and the Other “Yellow Players” in Neurodegenerative Diseases
Jayanti, S. D., Vítek, L., Tiribelli, C., & Gazzin, S. (2020) · Antioxidants · doi:10.3390/antiox9090900 · Cited by 42
Role of melatonin in TLR4-mediated inflammatory pathway in the MTPT-induced mouse model
Yıldırım, S., Özkan, A., Aytaç, G., Ağar, A., & Tanrιöver, G. (2021) · NeuroToxicology · doi:10.1016/j.neuro.2021.11.011 · Cited by 37
Multimodal detection of dopamine by sniffer cells expressing genetically encoded fluorescent sensors
Klein Herenbrink, C., Støier, J. F., Reith, W. D., Dagra, A., Gregorek, M. A. C., Cola, R. B., Patriarchi, T., Li, Y., Tian, L., Gether, U., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03488-5 · Cited by 35
Farrerol attenuates MPP+‐induced inflammatory response by TLR4 signaling in a microglia cell line
Cui, B., Guo, X., You, Y., & Fu, R. (2019) · Phytotherapy Research · doi:10.1002/ptr.6307 · Cited by 35
“TLR4 was found to be significantly upregulated and plays an important role in PD models both in vivo and in vitro (Mariucci, Pagiotti, Galli, Romani, & Conte, 2018; Noelker et al., 2013; Zhou et al., 2016).”
BackgroundImpact of sex on neuroimmune contributions to Parkinson’s disease
Bourque, M., Morissette, M., Soulet, D., & Paolo, T. D. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110668 · Cited by 37
Mariucci, G., Pagiotti, R., Galli, F., Romani, L. R., & Conte, C. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1057-7 · Cited by 40
“Moreover, TLR4 mediates cell death in aMPTPmodel of PD (Noelker et al. 2013) and its upregulation in microglia is a natural mechanism to boost the clearance of extracellular AS in ASPs (Stefanova et al. 2011).”
BackgroundLee, J., Kim, S. W., & Kim, K.-T. (2022) · Cells · doi:10.3390/cells11121902 · Cited by 34
Evidence for immune system alterations in peripheral biological fluids in Parkinson’s disease
Bartl, M., Xylaki, M., Bähr, M., Weber, S., Trenkwalder, C., & Mollenhauer, B. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105744 · Cited by 33
Pericytes take up and degrade α-synuclein but succumb to apoptosis under cellular stress
Stevenson, T. J., Johnson, R. H., Savistchenko, J., Rustenhoven, J., Woolf, Z., Smyth, L. C. D., Murray, H. C., Faull, R. L. M., Correia, J. A., Schweder, P. M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-20261-0 · Cited by 38
Pang, L., Zhang, N., Dong, N., Wang, D., Xu, D., Zhang, P., & Meng, X. (2015) · Inflammation · doi:10.1007/s10753-015-0280-4 · Cited by 33
“Recent studies have shown that the expression of TLR4 is upregulated in several central nervous system diseases, such as autoimmune disease, Parkinson’s disease, and ischemic and hemorrhagic brain injuries [4–8].”
BackgroundAssociation of TLR4 gene polymorphisms with sporadic Parkinson’s disease in a Han Chinese population
Zhao, J., Han, X., Li, X., Zhu, K., Liu, H., & Xie, A. (2015) · Neurological Sciences · doi:10.1007/s10072-015-2227-9 · Cited by 34
Vora, U., Vyas, V. K., Wal, P., & Saxena, B. (2022) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2022.01026 · Cited by 32
Conte, C., Ingrassia, A. M. T., Brevé, J. J. P., Bol, J. G. J. M., Huisman, E., van Dam, A., Beccari, T., & van de Berg, W. D. J. (2023) · Cells · doi:10.3390/cells12101368 · Cited by 36
Viana, S., Valero, J., Rodrigues‐Santos, P., Couceiro, P., Silva, A. M., Carvalho, F. D., Ali, S. F., Ribeiro, C., & Pereira, F. C. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13682 · Cited by 32
“In fact, TLRs most likely play a role in PD because a strong up-regulation of TLR’s was observed in the acute phase of MPTP injury and in postmortem PD striatal homogenates (Ros-Bernal et al. 2011; Noelker et al. 2013).”
BackgroundRole of G Protein-Coupled Receptors in Microglial Activation: Implication in Parkinson’s Disease
Gu, C., Chen, Y., Chen, Y., Liu, C., Zhu, Z., & Wang, M. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.768156 · Cited by 30
Let’s make microglia great again in neurodegenerative disorders
Guillot‐Sestier, M., & Town, T. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1792-x · Cited by 31
“This set of findings is given added weight, because TLR activation is strongly involved in immune responses during the course of neurodegenerative diseases (see ‘‘Receptor-mediated innate immune activation’’) (Letiembre et al. 2009; Zhao et al. 2010; Béraud et al. 2011; Lehmann et al. 2012; Noelker et al. 2013).”
Panaro, M. A., Aloisi, A., Nicolardi, G., Lofrumento, D. D., Nuccio, F. D., Pesa, V. L., Cianciulli, A., Rinaldi, R., Calvello, R., Fontani, V., et al. (2017) · Neuroscience Bulletin · doi:10.1007/s12264-017-0188-0 · Cited by 26
“Also, MPTP toxicity is less severe in TLR4-deficient mice than in WT mice [10].”
BackgroundKostuk, E. W., Cai, J., & Iacovitti, L. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1181-x · Cited by 29
“Furthermore, the interaction of MPTP/ MPP with the microglial receptor TLR4, a key receptor in the microglial activation pathway, has previously been established [39, 40].”
BackgroundChávez-Pichardo, M. E., Reyes-Bravo, D. Y., Mendoza-Trejo, M. S., Marín-López, A. G., Giòrdano, M., Hernández‐Chan, N. G., Domínguez-Marchan, K., Ortega-Rosales, L. C., & Rodríguez, V. M. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02806-2 · Cited by 28
Prydz, A., Stahl, K., Zahl, S., Skauli, N., Skare, Ø., Ottersen, O. P., & Amiry-Moghaddam, M. R. (2020) · Cells · doi:10.3390/cells9112418 · Cited by 28
“Our data are consistent with the findings by other groups showing that dopaminergic cell loss is lower in TLR4-deficient mice vs WT one week after treatment with MPTP (34% vs 45%) [73].”
ResultWidera, D., Martínez-Aguilar, R., & Cottrell, G. S. (2019) · Neural Regeneration Research · doi:10.4103/1673-5374.251290 · Cited by 26
Bidirectional Relation Between Parkinson's Disease and Glioblastoma Multiforme
Mencke, P., Hanss, Z., Boussaad, I., Sugier, P., Elbaz, A., & Krüger, R. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.00898 · Cited by 27
Chromosomal and gonadal factors regulate microglial sex effects in the aging brain
Ocañas, S. R., Ansere, V. A., Kellogg, C. M., Isola, J. V. V., Chucair‐Elliott, A. J., & Freeman, W. M. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.02.008 · Cited by 28
“as Alzheimer‟s disease (AD) [26-29], Parkinson‟s disease (PD) [30-32], and Multiple Sclerosis (MS) [33], all of which have sex biases in presentation and progression [34-43].”
Sharma, P. K., Kishore, A., De, I., Negi, S., Kumar, G., Bhardwaj, S., & Singh, M. P. (2023) · Neurochemistry International · doi:10.1016/j.neuint.2023.105604 · Cited by 24
Overview of the Gut–Brain Axis: From Gut to Brain and Back Again
Post, Z., Manfready, R. A., & Keshavarzian, A. (2023) · Seminars in Neurology · doi:10.1055/s-0043-1771464 · Cited by 30
Khan, M. M., Zaheer, S., Nehman, J., & Zaheer, A. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.07.003 · Cited by 25
“MPP+ is highly selective and toxic for nigrostriatal dopaminergic neurons both in vivo and in vitro (Noelker et al., 2013; Zhai et al., 2013).”
BackgroundTristão, F. S. M., Lazzarini, M., Martin, S., Amar, M., Stühmer, W., Kirchhoff, F., Gomes, L. C., Lanfumey, L., Prediger, R. D., Sepulveda-Diaz, J. E., et al. (2015) · Neurotoxicity Research · doi:10.1007/s12640-015-9557-5 · Cited by 23
TLR4 signaling mediates AP-1 activation in an MPTP-induced mouse model of Parkinson's disease
Zhao, X., Wang, F.-X., Cao, W., Zhang, Y., & Li, Y. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.01.010 · Cited by 23
How Toll-like receptors influence Parkinson’s disease in the microbiome–gut–brain axis
Zhang, Z., Liu, Z., Lv, A., & Fan, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1154626 · Cited by 27
“Animal experiments have found that intraperitoneal injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into mice with MPTP showed less microglial activation and less dopamine neuronal loss in the substantia–striatum nigra site of Toll-like receptor 4-deficient mice compared with wild-type mice (91).”
BackgroundInvestigating the TLR4/TAK1/IRF7 axis in NLRP3-Mediated Pyroptosis in Parkinson's Disease
Quan, W., Liu, Y., Li, J., Chen, D., Xu, J., Song, J. M., Chen, J., & Sun, S. (2023) · Inflammation · doi:10.1007/s10753-023-01918-y · Cited by 21
“Upregulation of TLR4 expression occurs in MPTP-induced PD models, and inhibiting TLR4 through gene knockout or siRNA silencing can improve MPTP-induced dopaminergic nerve cell death and microglia activation [55].”
Metadata
- Authors
- Noelker, C., Morel, L., Lescot, T., Osterloh, A., Alvarez-Fischer, D., Breloer, M., Henze, C., Depboylu, C., Skrzydelski, D., Michel, P. P., Dodel, R. C., Lu, L., Hirsch, E. C., Hunot, S., & Hartmann, A.
- Affiliations
- Centre National de la Recherche Scientifique (FR)
- Bernhard Nocht Institute for Tropical Medicine (DE)
- Philipps University of Marburg (DE)
- Corresponding author
- Hunot, Stéphane
- Hartmann, Andreas
- ORCID
- Venue
- Scientific Reports
- Published
- 2013-03-06
- Volume
- 3
- Issue
- 1
- Pages
- 1393-1393
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC3589722
- OpenAlex
- W2093718309
- Cited by
- 164
- References
- 23
- Citations by year
- 2026: 9 · 2025: 8 · 2024: 9 · 2023: 14 · 2022: 10 · 2021: 17 · 2020: 18 · 2019: 13 · 2018: 16 · 2017: 10 · 2016: 15 · 2015: 12 · 2014: 11 · 2013: 2
- FWCI
- 8.46
- Type
- journal article
- Language
- en
- Update notices
- correction (2023-01-16)
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-nd/3.0/ (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- HAL (submittedVersion, cc-by-nc-nd)
- Funders
- Michael J. Fox Foundation for Parkinson's Research
- Deutsche Forschungsgemeinschaft
- Institut National de la Santé et de la Recherche Médicale
- Centre National de la Recherche Scientifique
- Uniklinikum Giessen und Marburg
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- TLR4, Parkinson's disease, MPTP, dopaminergic neuron death, microglial activation, neuroinflammation, TLR4-deficient mice, substantia nigra, immune response
- MeSH terms
- Animals, Corpus Striatum, Dopamine, Homovanillic Acid, 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Cell Death, Microglia, Mice, Knockout, Parkinsonian Disorders, Toll-Like Receptor 4, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.